linjc16/ctgov huggingface dataset:
FINnish CardioVersion Study II

Study Overview
=================
Brief Summary
-----------------
This is a retrospective multi-center patient cohort study investigating patients with persistent atrial fibrillation (AF) and elective cardioversion (ECV). The aim is to identify clinical predictors for ineffective ECV to improve management quality of persistent AF.

Detailed Description
-----------------
Data was gathered from patient registries of two finnish university hospitals and two regional hospitals in a time period of 2003-2015. A data search was conducted using the ICD-10 code for atrial fibrillation and NCSP code for cardioversion. All patients with AF and performed cardioversion were eligible for the study. Initially, 2373 patients were captured after which all ECV cases were identified and included manually in the study using a structured electronic case report form. The study cohort comprised 1998 ECVs and 1342 patients. Follow-up data was gathered for 30 days after ECV and all strokes, transient ischemic attacks, arrhythmic complications, AF recurrences and failed cardioversions were recorded and subjected to careful exploration. IBM SPSS Statistics software version 22.0 was used to perform all analyses.

Official Title
-----------------
Finnish Elective Cardioversion for Persistent Atrial Fibrillation Study

Conditions
-----------------
Atrial Fibrillation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients with persistent (>48h) atrial fibrillation and elective electrical cardioversion Exclusion Criteria: Cardioversions for patients with acute (<48h) atrial fibrillation Pharmacological cardioversions

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Fatal or Non-fatal Stroke/TIA |  | 30 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Arrhythmic Complications | bradyarrhythmias, ventricular tachycardia and ventricular fibrillation | 24 hours | 
| Failure of Cardioversion | Assessed at discharge | 24 hours | 
| Recurrence of AF after ECV |  | 30 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Atrial Fibrillation, Cardioversion
Epidemiologic Registry PETHEMA LMA 2013

Study Overview
=================
Brief Summary
-----------------
Epidemiologic and retrospective multicenter registry of all patients diagnosed with de novo or secondary AML in the PETHEMA Group institutions. This study is a non-interventional research regarding diagnosis and therapeutic approach

Detailed Description
-----------------
To perform this registry, every patient diagnosed with AML in the participant institutions, regardless type of AML and treatment administered, must be reported. It will be required to registry the main characteristics of the patients and AML at diagnosis, as cytomorphologic, immunophenotypic, and cytogenetic results, according to the habitual practice of the centers. The treatment which has been administered by every center of the PETHEMA Group, even when it is considered as supportive care, and evolution of the disease will also be reported (relapse o death). PETHEMA Group will input all the reported information in data bases with the appropriate security.

Official Title
-----------------
Epidemiologic Registry of Patients Diagnosed With Acute Myeloid Leukemia (PETHEMA LMA 2013)

Conditions
-----------------
AML

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients diagnosed with acute myeloid leukemia Exclusion Criteria: no exclusion criteria

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Characteristics of the patients diagnosed with AML | To realize an epidemiologic and retrospective study to assess the characteristics of the patients diagnosed with AML and their disease, regardless the age or treatment | 3 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prognosis factors | To correlate clinical and biological features with outcome and evolution of the patients. | 3 years | 
| Risk factors | To identify and confirm the risk factors which are involved in the evolution of the disease. | 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
AML
Vascular Effects of Hesperidin in Metabolic Syndrome

Study Overview
=================
Brief Summary
-----------------
It has been suggested that cardiovascular risk factors either independently or in cluster (metabolic syndrome) increase the risk of both type 2 diabetes (DM2) and cardiovascular diseases (CVD). Consumption of citrus fruits is linked to reduced cardiovascular morbidity and mortality. Hesperidin is a flavanone abundant in citrus fruit with putative vasodilator actions in vitro. While molecular mechanisms of vascular actions of hesperidin begin to be explored, no data on in vivo vascular effect of this flavanone has been ever acquired.

Official Title
-----------------
Positive Vascular Effect of Hesperidin in Subjects Affected by Metabolic Syndrome

Conditions
-----------------
Endothelial Dysfunction, Metabolic Syndrome

Intervention / Treatment
-----------------
* Drug: Hesperidin
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Metabolic Syndrome (ATPIII criteria) BMI <35 Age 20-55 Exclusion Criteria: History of cancer. History of cardiovascular diseases. Any other acute or chronic illness which requires administration of steroids or other drugs able to interfere with glucose or lipid metabolism.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Hesperidin, 500 mg per day<br>500 mg daily of oral Hesperidin for 3 weeks | Drug: Hesperidin<br>* Administration of oral Hesperidin, 500 mg/daily<br>|
| Placebo Comparator: Placebo<br> | Drug: Placebo<br>* Administration of oral Placebo, 500 mg/daily<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety of oral supplementation of hesperidin |  | 3 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Endothelial function assessed by FMD %. Inflammatory status assessed by biochemical markers. |  | 3 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
endothelial, metabolic syndrome, hesperidin
Purdue University Parenting Program Attrition

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to examine the efficacy of techniques to enhance participation in parenting programs.

Detailed Description
-----------------
This project addresses the problem of involving parents in interventions that promote parenting effectiveness and child coping-competence in preschoolers as a means of reducing risk of child maltreatment (and related adverse developmental outcomes). Purdue University will examine the impact of partnership (organizational involvement in recruitment and retention), cash incentives, and a motivational goal setting component on participation and engagement in the Parenting Our Children to Excellence program, a group intervention for parents and caregivers of preschool children.

Official Title
-----------------
Purdue University Parenting Program Attrition and Compliance Efficacy Trial

Conditions
-----------------
Child Abuse

Intervention / Treatment
-----------------
* Behavioral: Motivational enhancements, parent training


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Parents with children 3-5 years old who attend centers in which interventions are offered Exclusion Criteria: See above. No other exclusion criteria will be used.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Single


Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: Motivational enhancements, parent training|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Engagement and participation in an 8-week parenting program |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Measures of parenting behavior and attitudes, incidents of child maltreatment, measures of child adjustment and functioning |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
parenting, motivation, child maltreatment, program attrition
Social Media Use of Acne Vulgaris Patients: Multicenter, Survey Work

Study Overview
=================
Brief Summary
-----------------
Acne Vulgaris is a chronic skin disease. However, chronic and repetitive due to the quality of life and psychological status of patients can affect. For this reason, patients carry out various research on their diseases on social media and follow programs on these issues in other media such as television and radio. However, there is no study on how much patients are interested in these publications, how much they trust them, and how they reach and organize information via social media. The aim of the study will be to clarify how and how patients with Acne Vulgaris use social media to obtain information about the diagnosis and treatment of their disease, the interaction of patient groups with each other, and how often social media is used, especially in which group of patients.

Official Title
-----------------
Social Media Use of Acne Vulgaris Patients: Multicenter, Survey Work

Conditions
-----------------
Acne Vulgaris

Intervention / Treatment
-----------------
* Behavioral: acne vulgaris


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: acne vulgaris patient Exclusion Criteria: who does not want to answer the questions

Ages Eligible for Study
-----------------
Minimum Age: 12 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: acne vulgaris|Social media use of acne vulgaris patients, a questionnaire will be asked the patients and try to learn how they use social media for getting information about their disease.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Social media use of acne vulgaris patients, a questionnaire will be asked the patients and try to learn how they use social media for getting information about their disease. |  | september 2020 |
French Digestive Polyposis Cohorte Family Adenomatous Polyposis With APC and MYH Gene Mutations , Cowden's Disease With PTEN Gene Mutation, Peutz Jeghers Disease With STK 11 Gene Mutation ,juvénil Polyposis With SMAD 4 Gene Mutation , Serrated and Hyperplastic Polyposis

Study Overview
=================
Brief Summary
-----------------
French cohorte about polyposis digestive diseases

Detailed Description
-----------------
Family Adenomatous Polyposis APC and MYH Genes Peutz Jeghers Disease Cowden Disease Festooned polyposis Juvenile polyposis Hyperplastic polyposis

Official Title
-----------------
French Digestive Polyposis Cohorte

Conditions
-----------------
Quality of Life

Intervention / Treatment
-----------------
* Other: Procedure surgery behavioral and genetic diagnosis
* Procedure: quality of life after different type of surgery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: APC Gene mutation MYH Homozygote mutation COWDEN Disease with PTEN gene mutation Peutz Jeghers Disease with STK 11 gene mutation Juvenile polyposis with SMAD 4 gene mutation Exclusion Criteria: heterozygote MYH Gene Mutation

Ages Eligible for Study
-----------------
Minimum Age: 12 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| digestive polyposis<br>Family adenomatous polyposis (APC or MYH genes) Peutz Jeghers Disease Cowden Disease Festooned Polyposis Juvenile Polyposis Hyperplastic Polyposis | Other: Procedure surgery behavioral and genetic diagnosis<br>* Observational Study<br>Procedure: quality of life after different type of surgery<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| genetic diagnosis or over 50 polyps in the stomach in the duodenum or in the colon |  | 10 years |
Arrhythmias in Myotonic Muscular Dystrophy

Study Overview
=================
Brief Summary
-----------------
Adult myotonic muscular dystrophy (Steinert's disease) is the most common inherited neuromuscular disorder. Cardiac rhythm disturbances occur frequently in this disease state and may be responsible for up to one-third of deaths. In this study, we intend to evaluate the utility of non-invasive electrocardiographic screening methods and history in predicting serious arrhythmic events.

Detailed Description
-----------------
The long term objectives of this population study is a more defined natural history, optimal diagnostic testing methodology, and methods of therapy for arrhythmias in individuals with myotonic muscular dystrophy. The goal is a more adequate definition of appropriate diagnosis and therapy for arrhythmias in order to decrease the likelihood of cardiac morbidity and mortality in this disorder. The specific aims of the study involve an initial survey of individuals with myotonic muscular dystrophy detailing multiple factors. Non-invasive electrocardiographic testing will be done. Using this initial data and subsequent follow-up data collected yearly the cohort of patients will be followed as to arrhythmia development over a minimum of five years and likely longer with a long-term registry and evaluation of National Death Records and Ancestry.com. This project is unique in that it characterizes a non-neurologic abnormality associated with a neuromuscular disease, myotonic muscular dystrophy.

Official Title
-----------------
A Registry of Arrhythmias in Myotonic Muscular Dystrophy

Conditions
-----------------
Muscular Dystrophy, Arrhythmia, Sudden Cardiac Death

Intervention / Treatment
-----------------
* Other: Screening


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18 and over Willing to sign informed consent Have a previous diagnosis of myotonic muscular dystrophy Exclusion Criteria: Under age 18. Unwilling to sign consent. Unwilling to commit to long-term follow-up.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Registry of Arrhythmias<br>Screening of individuals with myotonic muscular dystrophy to evaluate the utility of non-invasive electrocardiographic screening methods and history in predicting serious arrhythmic events. | Other: Screening<br>* Electrocardiography Blood Test<br>* Other names: Blood Test;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluate incidence of arrhythmias in myotonic muscular dystrophy |  | 3 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluate with diagnostic non-invasive electrocardiogram (ECG) |  | 3 Years |
Effect of Visceral and Parietal Peritoneum Suturation on Postoperative Vital Signs

Study Overview
=================
Brief Summary
-----------------
In this study the investigators want to asses the effect of peritonisation at c-section on postoperative vital signs which was thought to be an indirect finding secondary to increased sympathetic activity originated from pain caused by stretched peritoneum.

Detailed Description
-----------------
At c-section subject will be randomised into four groups: Group1: Only visceral peritoneum will be closed Group 2: Only parietal peritoneum will be closed Group 3: Both of them will be closed Group 4: None of them will be closed During the postoperative period all patients will undergo vital sign screening including urine output, blood pressure measurement, pulse rate and VAS score will be determined at post operative 6th hour and 24th hour.

Official Title
-----------------
Effect of Visceral and Parietal Peritoneum Suturation on Postoperative Vital Signs

Conditions
-----------------
Postoperative Pain

Intervention / Treatment
-----------------
* Procedure: Group 1: Only visceral peritoneum will be closed
* Procedure: Group 2 : Only parietal peritoneum will be closed
* Procedure: Group 3 : Both of them will be closed
* Procedure: Group 4: None of them will be closed


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women underwent uncomplicated c-section Exclusion Criteria: Patient with systemic Diseases Pregnant with Obstetric complications Pregnant with two or more previous c-sections

Ages Eligible for Study
-----------------
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Screening
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Only visceral peritoneum will be closed<br>Group1: Only visceral peritoneum will be closed | Procedure: Group 1: Only visceral peritoneum will be closed<br> <br> |
| Experimental: Only parietal peritoneum will be closed<br>Group 2: Only parietal peritoneum will be closed | Procedure: Group 2 : Only parietal peritoneum will be closed<br> <br> |
| Experimental: Both of them will be closed<br>Group 3: Both of them will be closed | Procedure: Group 3 : Both of them will be closed<br> <br> |
| Experimental: None of them will be closed<br>Group 4: None of them will be closed | Procedure: Group 4: None of them will be closed<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Postoperative vital sign (arterial tension) |  | First postoperative hour |
Identification by Transcriptomic Approach of New Prognostic and Predictive Markers in a Cohort of Atypical Meningiomas

Study Overview
=================
Brief Summary
-----------------
Determine by a transcriptomic approach new prognostic and predictive markers in atypical meningiomas (WHO grade II). Retrospective observational study, on a cohort of 85 atypical meningiomas. Transcriptomic study first, on cryopreserved tumor samples. Then identify, thanks to the transcriptomic study, prognostic and predictive factors (study of the link between the quantity of certain RNA transcripts and progression-free survival). Finally, set up immunohistochemical applications, which can be used routinely by the pathologist.

Official Title
-----------------
Identification by Transcriptomic Approach of New Prognostic and Predictive Markers in a Cohort of Atypical Meningiomas and Immunohistochemical Applications

Conditions
-----------------
Meningioma Atypical

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Primary operated patients for an atypical meningioma (WHO grade II) in the Neurosurgery department of the University Hospital of Nancy. At least one postoperative follow-up visit. Adult patients (>18 yo) at the time of the intervention. Surgical excision. Exclusion Criteria: History of meningioma in the same location. Neo-adjuvant treatment. Absence of non-objection form.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Progression-free survival | Progression being defined by a growth (mm3) of the tumor objectified by imaging. | through study completion an average of 5 years. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Tumor volume assessed by imaging pre- and post-operative | mm3; RECIST criteria | before and within 3 months after surgery | 
| mRNA quantities of transcripts of interest | µg.mL-1 | through study completion, an average of 1 year | 
| Radiotherapy-induced toxicity | CTCAE scale (Common Terminology Criteria for Adverse Events) v 4.0 | within 5 years after radiotherapy | 
| Dose of corticosteroids before and after radiotherapy | in mg | within 6 months before and after radiotherapy | 
| Intra-observer, inter-observer and inter-laboratory intra-class correlation coefficients of immunohistochemical markers. | Kappa coefficient | through study completion, an average of 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Transcriptome